389 related articles for article (PubMed ID: 18005142)
1. Does early migraine treatment shorten time to headache peak and reduce its severity?
Hu XH; Ng-Mak D; Cady R
Headache; 2008 Jun; 48(6):914-20. PubMed ID: 18005142
[TBL] [Abstract][Full Text] [Related]
2. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
[TBL] [Abstract][Full Text] [Related]
3. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
4. Can migraineurs accurately identify their headaches as "migraine" at attack onset?
Ng-Mak DS; Cady R; Chen YT; Ma L; Bell CF; Hu XH
Headache; 2007 May; 47(5):645-53. PubMed ID: 17501845
[TBL] [Abstract][Full Text] [Related]
5. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg.
Schreiber CP; Cady RK
Clin Ther; 2007; 29 Suppl():2511-9. PubMed ID: 18164918
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
8. Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention.
Cady RK; Freitag FG; Mathew NT; Elkind AH; Mao L; Fisher AC; Biondi DM; Finlayson G; Greenberg SJ; Hulihan JF
Headache; 2009 Mar; 49(3):350-63. PubMed ID: 19220503
[TBL] [Abstract][Full Text] [Related]
9. Perimenstrual eletriptan prevents menstrual migraine: an open-label study.
Marcus DA; Bernstein CD; Sullivan EA; Rudy TE
Headache; 2010 Apr; 50(4):551-62. PubMed ID: 20236337
[TBL] [Abstract][Full Text] [Related]
10. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Rizatriptan 10 mg administered early in a migraine attack.
Cady R; Martin V; Mauskop A; Rodgers A; Hustad CM; Ramsey KE; Skobieranda F
Headache; 2006 Jun; 46(6):914-24. PubMed ID: 16732837
[TBL] [Abstract][Full Text] [Related]
12. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study.
Spierings EL; Keywood C
Pain Med; 2009; 10(4):633-8. PubMed ID: 19453958
[TBL] [Abstract][Full Text] [Related]
13. Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.
Ng-Mak DS; Hu XH; Chen Y; Ma L; Solomon G
Int J Clin Pract; 2007 Jul; 61(7):1091-111. PubMed ID: 17537184
[TBL] [Abstract][Full Text] [Related]
14. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan.
Goldstein J; Tiseo PT; Albert KS; Li C; Sikes CR
Headache; 2006; 46(7):1142-50. PubMed ID: 16866718
[TBL] [Abstract][Full Text] [Related]
15. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
[TBL] [Abstract][Full Text] [Related]
16. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
Goadsby PJ
Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
[TBL] [Abstract][Full Text] [Related]
17. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
18. The Migraine Intervention Score - a tool to improve efficacy of triptans in acute migraine therapy: the ALADIN study.
Göbel H; Heinze A
Int J Clin Pract; 2011 Aug; 65(8):879-86. PubMed ID: 21762313
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
20. Examining the interrelationship of migraine onset, duration, and time to treatment.
Landy SH; Runken MC; Bell CF; Higbie RL; Haskins LS
Headache; 2012 Mar; 52(3):363-73. PubMed ID: 22077159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]